ORGENTEC Diagnostika GmbH

Carl-Zeiss-Straße 49-51 55129 Mainz - Germany Phone: +49 (0) 61 31 / 92 58-0 Fax: +49 (0) 61 31 / 92 58-58 Internet: www.orgentec.com



For research use only. Not for diagnostic procedures.

RUO 544 **ENA-4-Profile**

INTENDED USE

i

ENA-4-Profile is an ELISA test system for the qualitative measurement of IgG class autoantibodies directed against the extractable nuclear antigens SS-A (52 and 60 kDa, Ro), SS-B (La), Sm and RNP/Sm in human serum or plasma. This product is intended for research use only. Not for diagnostic procedures. AchPurpose



Distributed By: IBL-America, Inc. 8201 Central Ave NE, Suite P Minneapolis, MN 55432, USA tionalReseard info@ibl-america.com (888) 523 1246

SYMBOLS USED ON LABELS

***	Manufacturer	MICROPLATE	Microplate
		CALIBRATOR	Calibrator
REF	Catalogue number	CALIBRATOR	Calibrator
		CALIBRATOR	Calibrator
∑ 96	Sufficient for 96 determinations	CALIBRATOR	Calibrator
LOT	Batch code		
\Box	Use by	CONTROL +	Control positive
2°C	Temperature limitation	CONTROL -	Control negative
*	Keep away from sunlight		Sample Buffer P
\otimes	Do not reuse	CONJUGATE	Enzyme Conjugate
M	Date of manufacture	ТМВ	TMB Substrate
		STOP	Stop solution
i	Consult instructions for use	WASH	Wash Buffer
		RTU	Ready to use

PRINCIPLE OF THE TEST

Extractable nuclear antigens SS-A (52 and 60 kDa), SS-B, Sm, RNP/Sm, are bound to microwells.

The determination is based on an indirect enzyme linked immune reaction with the following steps:

Specific antibodies in the sample bind to the antigen coated on the surface of the reaction wells. After incubation, a washing step removes unbound and unspecifically bound serum or plasma components. Subesquently added enzyme conjugate binds to the immobilized antibody-antigen-complexes. After incubation, a second washing step removes unbound enzyme conjugate. After addition of substrate solution the bound enzyme conjugate hydrolyses the substrate forming a blue coloured product. Addition of an acid stopps the reaction generating a yellow end-product. The intensity of the yellow color

correlates with the concentration of the antibody-antigen-complex and can be measured photometrically at 450 nm.

WARNINGS AND PRECAUTIONS

- · All reagents of this kit are intended for professional use only.
- Components containing human serum were tested and found negative for HBsAg, HCV, HIV1 and HIV2 by FDA approved methods. No test can guarantee the absence of HBsAg, HCV, HIV1 or HIV2, and so all human serum based reagents in this kit must be handled as though capable of transmitting infection.
- Bovine serum albumin (BSA) used in components has been tested for BSE and found negative.
- Avoid contact with the substrate TMB (3,3',5,5'-Tetramethyl-benzidine).
- Stop solution contains acid, classifiaction is non-hazardous. Avoid contact with skin.
- Control, sample buffer and wash buffer contain sodium azide 0.09% as preservative. This concentration is classified as non-hazardous.
- Enzyme conjugate contains ProClin 300 0.05% as preservative. This concentration is classified as non-hazardous.

During handling of all reagents, controls and serum samples observe the existing regulations for laboratory safety regulations and good laboratory practice:

- First aid measures: In case of skin contact, immediately wash thoroughly with water and soap. Remove contaminated clothing and shoes and wash before reuse. If system fluid comes into contact with skin, wash thoroughly with water. After contact with the eyes carefully rinse the opened eye with running water for at least 10 minutes. Get medical attention if necessary.
- · Personal precautions, protective equipment and emergency procedures:

Observe laboratory safety regulations. Avoid contact with skin and eyes. Do not swallow. Do not pipette by mouth. Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents are handled. When spilled, absorb with an inert material and put the spilled material in an appropriate waste disposal.

- Exposure controls / personal protection: Wear protective gloves of nitril rubber or natural latex.
- Wear protective glasses. Used according to intended use no dangerous reactions known.
- · Conditions to avoid: Since substrate solution is light-sensitive. Store in the dark.
- For disposal of laboratory waste the national or regional legislation has to be observed.

Observe the guidelines for performing quality control in medical laboratories by assaying control sera.



CONTENTS OF THE KIT

		••	
RUO 544	∑ 96	Sufficient for 96 determinations	
MICROPLATE	1	One divisible microplate consisting of 12 modules of 8 wells each. Ready to use.	
		Color code on module	
CALIBRATOR	1 ml	Calibrator SS-A (cut-off), containing SS-A antibodies in a serum/buffer matrix (PBS,	
		BSA, detergent, NaN3 0.09%), yellow. Ready to use.	
CALIBRATOR	1 ml	Calibrator SS-B (cut-off), containing SS-B antibodies in a serum/buffer matrix (PBS,	
		BSA, detergent, NaN3 0.09%), yellow. Ready to use.	
CALIBRATOR	1 ml	Calibrator Sm (cut-off), containing Sm antibodies in a serum/buffer matrix (PBS, BSA,	
		detergent, NaN3 0.09%), yellow. Ready to use.	
CALIBRATOR	1 ml	Calibrator RNP/Sm (cut-off), containing RNP/Sm antibodies in a serum/buffer matrix	
		(PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.	
CONTROL +	1.5 ml	Control positive, containing ENA antibodies in a serum/buffer matrix (PBS, BSA,	
		detergent, NaN3 0.09%), yellow. Ready to use.	
CONTROL -	1.5 ml	Control negative, containing ENA antibodies in a serum/buffer matrix (PBS, BSA,	
		detergent, NaN3 0.09%), yellow. Ready to use.	
DILUENT	20 ml	Sample Buffer P, containing PBS, BSA, detergent, preservative sodium azide 0.09%, yellow, concentrate (5 x).	
CONJUGATE	15 ml	Enzyme Conjugate containing anti-human IgG antibodies, HRP labelled; PBS, BSA,	
		detergent, preservative PROCLIN 0.05%, light red. Ready to use.	
ТМВ	15 ml	TMB Substrate; containing 3,3', 5,5'- Tetramethylbenzidin, colorless. Ready to use.	
STOP	15 ml	Stop solution; contains acid. Ready to use.	
WASH	20 ml	Wash Buffer, containing Tris, detergent, preservative sodium azide 0.09%; 50 x conc.	
	1	Certificate of Analysis	
		C	

MATERIALS REQUIRED

- · Microplate reader capable of endpoint measurements at 450 nm; optional: reference filter at 620 nm
- · Data reduction software
- Multi-channel dispenser or repeatable pipette for 100 μl
- Vortex mixer
- Pipettes for 10 $\mu l,$ 100 μl and 1000 μl . (
- Laboratory timing device
- · Distilled or deionised water
- · Measuring cylinder for 1000 ml and 100 ml
- · Plastic container for storage of the wash solution

This ELISA assay is suitable for use on open automated ELISA processors. Each assay has to be validated on the respective automated system. Detailed information is provided upon request.

SPECIMEN COLLECTION, STORAGE AND HANDLING

- · Collect whole blood specimens using acceptable medical techniques to avoid hemolysis.
- Allow blood to clot and separate the serum or plasma by centrifugation.
- Test serum should be clear and non-hemolyzed. Contamination by hemolysis or lipemia should be avoided, but does not interfere with this assay.
- Specimens may be refrigerated at 2-8°C for up to five days or stored at -20°C up to six months.
- Avoid repetitive freezing and thawing of serum or plasma samples. This may result in variable loss of antibody activity.
- Testing of heat-inactivated sera is not recommended.

STORAGE AND STABILITY

- Store test kit at 2-8°C in the dark.
- · Do not expose reagents to heat, sun, or strong light during storage and usage.
- · Store microplate sealed and dessicated in the clip bag provided.
- Shelf life of the unopended test kit is 18 months from day of production.

Unopened reagents are stable until expiration of the kit. See labels for individual batch.

• Diluted Wash Buffer and Sample Buffer are stable for at least 30 days when stored at 2-8°C. We recommend consumption on the same day.

PROCEDURAL NOTES

- Do not use kit components beyond their expiration dates.
- Do not interchange kit components from different lots and products.
- All materials must be at room temperature (20-28°C) prior to use.
- Prepare all reagents and samples. Once started, performe the test without interruption.
- Double determinations may be done. By this means pipetting errors may become obvious.
- Perform the assay steps only in the order indicated.
- Always use fresh sample dilutions.
- Pipette all reagents and samples into the bottom of the wells.
- To avoid carryover or contamination, change the pipette tip between samples and different kit controls.
- Wash microwells thoroughly and remove the last droplets of wash buffer.
- All incubation steps must be accurately timed.
- Do not re-use microplate wells.

PREPARATION OF REAGENTS

WASH

Dilute the contents of one vial of the buffered wash solution concentrate (50x) with distilled or deionised water to a final volume of 1000 ml prior to use.

DILUENT

Sample Buffer P: Prior to use dilute the contents (20 ml) of one vial of sample buffer 5x concentrate with distilled or deionised water to a final volume of 100 ml.

Preparation of samples

Dilute samples 1:100 before the assay: Put 990 µl of prediluted sample buffer in a polystyrene tube and add 10 µl of sample. Mix well. Note: Calibrators / Controls are ready to use and need not be diluted.

Formationaline

TEST PROCEDURE

1.


Prepare enough microplate modules for all calibrators / controls and samples.

- Pipette 100 μ l of calibrators, controls and prediluted samples into the wells. Incubate for 30 minutes at room temperature (20-28 °C).
- Discard the contents of the microwells and wash 3 times with 300 μ l of wash solution.
- 2. Dispense 100 µl of enzyme conjugate into each well.
 - Incubate for 15 minutes at room temperature.
 - Discard the contents of the microwells and wash 3 times with 300 μl of wash solution.
- 3. Dispense 100 µl of TMB substrate solution into each well.
- Incubate for 15 minutes at room temperature
- 4. Add 100 μl of stop solution to each well of the modules

Incubate for 5 minutes at room temperature.

Read the optical density at 450 nm (reference 600-690nm) and calculate the results.

The developed colour is stable for at least 30 minutes. Read during this time.



VALIDATION

Test results are valid if the optical densities at 450 nm for calibrators / controls and the results for controls comply with the reference ranges indicated on the Certificate of Analysis enclosed in each test kit. If these quality control criteria are not met the assay run is invalid and should be repeated.

CALCULATION OF RESULTS

For qualitative results: for each antigen of the profile the optical density (OD) of a sample is compared to the OD of the antigen-specific Calibrator

Negative: OD sample < OD Calibrator

Positive: OD sample ≥ OD Calibrator

For detailed results: the optical density of a sample is expressed as Index value

Index = OD sample / OD Calibrator

ASSAY CHARACTERISTICS

CALIBRATION

The assay system is calibrated against the internationally recognized reference sera from CDC, Atlanta USA.

Measuring range

Calculation range: not applicable

Interfering substances

No interference has been observed with haemolytic (up to 1000 mg/dl) or lipemic (up to 3 g/dl triglycerides) sera or plasma, or bilirubin (up to 40 mg/dl) containing sera or plasma. Nor have any interfering effects been observed with the use of anticoagulants (Citrate, EDTA, Heparine). However for practical reasons it is recommended that grossly hemolyzed or lipemic samples should be avoided.

LIMITATIONS OF THE PROCEDURE

For research use only. Not for diagnostic procedures.

REFERENCES

1. Alba P, Bento L, Cuadrado MJ, Karim Y, Tungekar MF, Abbs I et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 2003; 62(6):556-560.

2. Antico A, Platzgummer S, Bassetti D, Bizzaro N, Tozzoli R, Villalta D. Diagnosing systemic lupus erythematosus: new-generation immunoassays for measurement of anti-dsDNA antibodies are an effective alternative to the Farr technique and the Crithidia luciliae immunofluorescence test. Lupus 2010; 19(8):906-912.

3. Brouwer R, Hengstman GJ, Vree EW, Ehrfeld H, Bozic B, Ghirardello A et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001; 60(2):116-123.

4. Castro C, Gourley M. Diagnostic testing and interpretation of tests for autoimmunity. J Allergy Clin Immunol 2010; 125(2 Suppl 2):S238-S247.

5. Defendenti C, Atzeni F, Spina MF, Grosso S, Cereda A, Guercilena G et al. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev 2011; 10(3):150-154.

6. Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapaa-Dahlqvist S. Autoantibodies predate the onset of Systemic Lupus Erythematosus in northern Sweden. Arthritis Research & Therapy 2011; 13 (1):R30.

7. Haugbro K, Nossent JC, Winkler T, Figenschau Y, Rekvig OP. Anti-dsDNA antibodies and disease classification in antinuclear antibody positive patients: the role of analytical diversity. Ann Rheum Dis JID - 0372355 2004; 63(4):386-394.

8. Ippolito A, Wallace DJ, Gladman D, Fortin PR, Urowitz M, Werth V et al. Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. Lupus 2011; 20(3):250-255.

9. Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A. Fifty years of anti-ds DNA antibodies: are we approaching journey's end? Rheumatology (Oxford) 2007; 46(7):1052-1056.

10. Kattah NH, Kattah MG, Utz PJ. The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases. Immunol Rev 2010; 233(1):126-145.

11. Kumar Y, Bhatia A, Minz RW. Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited. Diagn Pathol 2009; 4:1.

12. Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis 2010; 69:1420 -1422.

13. Petri M, Magder L. Classification criteria for systemic lupus erythematosus: a review. Lupus 2004; 13(11):829 -837.

14. Poole BD, Schneider RI, Guthridge JM, Velte CA, Reichlin M, Harley JB et al. Early targets of nuclear RNP humoral autoimmunity in human systemic lupus erythematosus. Arthritis Rheum 2009; 60(3):848-859.

15. Putova I, Dostal C, Becvar R. Prevalence of antinucleosome antibodies by enzyme-linked immunosorbent assays in patients with systemic lupus erythematosus and other autoimmune systemic diseases. Ann N Y Acad Sci 2007; 1109:275-286.

16. Reveille JD. Predictive value of autoantibodies for activity of systemic lupus erythematosus. Lupus JID - 9204265 2004; 13(5):290-297.

17. Simon JA, Cabiedes J, Ortiz E, Alcocer-Varela J, Sanchez-Guerrero J. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology (Oxford) 2004; 43(2):220-224.

18. Sinclair D, Saas M, Williams D, Hart M, Goswami R. Can an ELISA replace immunofluorescence for the detection of anti-nuclear antibodies?--The routine use of anti-nuclear antibody screening ELISAs. Clin Lab 2007; 53 (3-4):183-191.

19. Tozzoli R, Bizzaro N, Tonutti E, Villalta D, Bassetti D, Manoni F et al. Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol 2002; 117 (2):316-324.

20. Maidhof W., Hilias O. Lupus: an pverview of the disease and management options. P T 2012; 37(4):240-9.

21. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64(6):797-808.

For Informational Research Purposes Only